Timothy Leary had nothing on 1950s radiologist
When LSD guru Timothy Leary urged the nation's youth to “turn on, tune in, and drop out” in the 1960s, he was following a path already tread by radiologist and internist Dr. Mortimer A. Hartman, who dabbled in psychology and sold LSD to Hollywood A-listers, including Cary Grant.
When LSD guru Timothy Leary urged the nation's youth to “turn on, tune in, and drop out” in the 1960s, he was following a path already tread by radiologist and internist Dr. Mortimer A. Hartman, who dabbled in psychology and sold LSD to Hollywood A-listers, including Cary Grant.
Grant's escapades with LSD are chronicled in Evenings with Cary Grant: Recollections in His Own Words and by Those Who Knew Him Best, a book by Nancy Nelson that is excerpted in the August issue of Vanity Fair. Describing his LSD experiences, Grant said, “I ran the gamut of emtions, from deep pain with tears to light-headed laughter. For me, it was an experiment, and it was always monitored under Dr. Hartman’s care.” Dr.Hartman concluded, “LSD was not recreational for Cary. It was a very serious experiment.” Once LSD became illegal in California, Grant and Hartman discontinued its use, the article said.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
